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Abstract
Tau protein was scanned for highly amyloidogenic sequences in amphiphilic motifs (X)nZ,
Z(X)nZ (n≥2) or (XZ)n (n≥2), where X is a hydrophobic residue and Z is a charged or polar
residue. N-acetyl peptides homologous to these sequences were used to study aggregation.
Transmission electron microscopy (TEM) showed 7 peptides, in addition to well known primary
nucleating sequences c275VQIINK (AcPHF6*) and Ac306VQIVYK (AcPHF6), formed fibers,
tubes, ribbons or rolled sheets. Of the peptides shown by TEM to form amyloid, Ac10VME,
AcPHF6*, Ac375KLTFR, and Ac393VYK were found to enhance the fraction of β-structure of
AcPHF6 formed at equilibrium, and Ac375KLTFR was found to inhibit AcPHF6 and AcPHF6*
aggregation kinetics in a dose-dependent manner, consistent with its participation in a hybrid steric
zipper model. Single site mutants were generated which transformed predicted amyloidogenic
sequences in tau into non-amyloidogenic ones. A M11K mutant had fewer filaments and showed a
decrease in aggregation kinetics and an increased lag time compared to wild type tau, while a
F378K mutant showed significantly more filaments. Our results infer that sequences throughout
tau, in addition to PHF6 and PHF6*, can seed amyloid formation or affect aggregation kinetics or
thermodynamics.
Tau is a microtubule-associated protein that regulates microtubule stability, neurite growth
and other microtubule-dependent functions. The human protein exists as six isoforms,
consisting of an acidic N-terminal containing up to two 29-amino acid inserts and a basic
microtubule binding region (MTBR) containing either three or four tandem 31 (or 32) amino
acid pseudo-repeats (R1–R4) near the C-terminal (1–4). Normal phosphorylation of tau by
proline-directed kinases (GSK-3β, MAPK, CDK5) and by non-proline directed kinases
(PKA, MARK, SADK, and Src family of tyrosine kinases) may affect tau’s affinity for
microtubules and regulate the dynamics of microtubules, establish neuronal polarity, axonal
outgrowth and axonal transport in mature neurons (5,6). “Hyperphosphorylation” of tau and
cleavage of tau by cell proteases (thrombin-like proteases, cathepsins, caspases and calpains)
appear to lead to the aggregation of tau into dimers, oligomers, and paired helical filaments
(PHFs) which make up the neurofibrillary tangles (NFTs) in patients with Alzheimer’s
disease (AD) and other tauopathies (7–9). Recent evidence suggests that, while smaller
aggregates of tau occur as early events during the course of the disease and are responsible
for neurotoxicity, larger filaments and filament bundles are neuroprotective (10–13).
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While early work showed recombinant tau and tau isolated from microtubule preparations to
be largely unstructured or “natively unfolded”, aggregated forms of the protein displayed
physical characteristics of amyloid, including a cross-β X-ray diffraction pattern (14–18).
Nucleating sequences or “hot spots” in the protein sequence, 275VQIINK (PHF6*) in R2
and 306VQIVYK (PHF6) in R3, were identified, and it has been shown that one or more of
these sequences is essential for filament formation (19–22). Previous work from our
laboratory has shown that an N- and C-terminal blocked peptide AcPHF6 aggregates into
filaments displaying a cross-β-X-ray pattern and, in the presence of smaller peptides,
produces twisted filaments with morphology similar to PHFs (23). More recent X-ray work
on the PHF6 peptide has shown it to pack in a “steric zipper” with antiparallel layers of
parallel, in-register aligned peptides (24–26), while EPR and NMR of tau protein has shown
that PHF6 or PHF6 and PHF6* interact intermolecularly in a parallel or antiparallel fashion
in protein aggregates (12,27–29). Furthermore, NMR and FRET studies have shown that
while the backbone of the protein monomer appears to be in rapid exchange with an
ensemble of conformations, the average conformation is one in which the C-terminal is
folded over the MTBR and the N-terminal is folded over the C-terminal in a “paperclip”
conformation (11,12,30–34). It has been hypothesized that phosphorylation of tau at specific
sites opens the paperclip conformation, exposing the MTBR and catalyzing aggregation of
the protein or exposing a portion of the N-terminal which inhibits anterograde fast axonal
transport, resulting in neurotoxicity (30,35).
Tau lacking the PHF6 still has the ability to form aggregates, implying that PHF6* or other
sequences in tau can nucleate tau polymerization or stabilize oligomeric structures (20–
22,36). A C-terminal tail peptide that included the PHF6-like sequence 392IVYK395 but
lacked either PHF6 or PHF6*, was found to form straight filaments containing a high degree
of β-sheet conformation (37). While deletion of the C-terminal tail at Lys321 enhances
aggregation, a similar deletion at Asp314 renders tau incapable of aggregation, suggesting
that 314DLSKVTS is essential for PHF formation. A recent NMR study on full length tau
has shown that several other sequences including 336QVEVKSEKLD, 86GKQAAAQ,
and 224KKVAVVR are in the β-sheet conformation (31). Surprisingly, deletion
of 336QVEVKSE from the MTBR of R4 or the entire R4 sequence enhanced polymerization,
suggesting that sequences within R4 have an inhibitory effect (21,38,39).
In a previous study amyloidogenic propensities of individual amino acid residues were
extrapolated from measured properties of a family of AcPHF6 peptides (VQIVXK, where X
is the substituted residue) using a principal component analysis approach (40). Using
individual amino acid propensities, amyloidogenic propensities of sequences within tau
conforming to structural motifs, (X)nZ, Z(X)nZ or (XZ)n (n≥2), where X is a hydrophobic
residue and Z is a charged or polar amino acid, were estimated. The goal of the present study
was to determine if sequences within tau predicted to have high amyloidogenic propensities
could, in fact, seed filaments or interact with other known nucleating sequences within the
protein (PHF6 and PHF6*). Surprisingly, we found that peptides with these amyloidogenic
sequences were able to form all different morphological expressions of amyloid including
filaments, tubes, ribbons and rolled sheets. Furthermore, CD difference spectra and kinetics
measurements showed that some of these peptides were able to interact with PHF6 or
PHF6* peptides in a manner which either enhanced or inhibited aggregation. We found that
point mutations in tau which severely reduce the amyloid propensities of these sequences
affect the kinetics of aggregation or the number of filaments formed at equilibrium and we
interpret these results in terms of inter- and intramolecular interactions.
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Fmoc-amino acids were purchased from EMD Chemicals (Gibbstown, NJ). High molecular
weight heparin (HMWH; porcine mucosa; 18 kDa average MW; 6–30 kDa range) was
obtained from Sigma-Aldrich Chemical (St. Louis, MO) and was used without further
purification. All other chemicals and buffers were of Reagent grade.
Amyloidogenic propensities of sequences in tau protein
Tau protein was scanned for sequences which satisfied the amphiphilic motifs (X)nZ,
Z(X)nZ or (XZ)n (n≥2), where X is a hydrophobic and Z is a polar or charged amino acid
residue. Amyloidogenic propensities of sequences satisfying these motifs were evaluated
using the sum of the absolute values of their constituent residue PC1 scores (40).
Peptide Synthesis
N-acetyl peptide amides corresponding to potentially nucleating sequences selected in tau
were prepared according to previously published procedures and purified by reverse-phase
HPLC using a water-acetonitrile gradient (23,40,41). Purity was checked using ESI-MS or
MALDI-TOF MS.
Far-UV CD spectroscopy
Stock solutions of the peptides were prepared (~1–5 mg/mL) in deionized water. Final
peptide concentrations were determined by absorbance using published molar extinction
coefficients for tyrosine [ε276 of 1390 M−1cm−1] or for the peptide bond [ε192 of 7110
M−1cm−1](42,43). For CD measurements, peptide stocks were diluted to 100 μM in 5 mM
MOPS/0.15 M NaCl, pH 7.2 (MOPS-Cl buffer) containing 0.1 mg/mL of heparin. Samples
were transferred to a 0.1 cm path length quartz cell and bath sonicated for 1 min. Far-UV
CD spectra were acquired an AVIV 202 CD spectrophotometer, following a 1 h incubation
at room temperature in (23,40,44). CD measurements of peptide binary mixtures were
prepared in a similar manner with each of the peptides present at 100 μM. In order to
calculate mean residue molar ellipticity, the total number of residues was set to the sum of
the total number of residues in the peptides included in the mixture.
TEM
Samples for TEM were prepared from peptide stock solutions in MOPS-Cl buffer containing
0.3 mg/mL heparin. Following incubation overnight at room temperature, samples were
loaded onto carbon-coated Formvar copper grids (200 mesh) and stained with 2% wt/wt
uranyl acetate. A JEOL 1200 EX scope interfaced to a digital camera was used to visualize
samples. Distance measurements were made using Adobe Photoshop software (Adobe, Inc.,
San Jose, CA).
Kinetics of tau peptide aggregation
Polymerization kinetics were measured by monitoring the increase in Thioflavin S (ThS)
fluorescence at 490 nm (440 nm excitation) in a manner similar to that used to follow
aggregation in other amyloid-forming peptides and proteins (40,41,45–47). For each
peptide, a 1 mg/mL sample stock solution was filtered through a Millipore Ultrafree-MC
100,000 NMWL filter unit (Billerica, MA) by centrifuging for 10 minutes at 14,500 rpm,
using an Eppendorf MiniSpin plus bench top centrifuge (Westbury, NY). Following
filtration, the concentrations of the peptides were determined by UV absorbance. Stock
solutions were then diluted in 200 μL wells of a 96-well clear bottom ELISA plate such that
the final concentrations were 100 μM peptide, 0.3 mg/mL heparin, 100 μM ThS, in MOPS-
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Cl buffer or in 5 mM sodium phosphate containing 0.15 M NaCl, pH 3.0 (phosphate-Cl
buffer). Fluorescence data were collected in triplicate in kinetic mode, using a Molecular
Devices SPECTRA Max Gemini XPS spectrofluorimeter (Sunnyvale, CA), with
measurements taken at 15 s intervals. Mixing between readings was accomplished using a
1/8″ PTFE Grade 2 polished mixing bead (Orange Products, Allentown, PA). In order to
minimize time before the first data was collected, peptide solutions were added just before
the commencement of the readings. A blank containing only buffer, heparin and ThS was
recorded concurrently with the samples. Baseline corrected kinetic data were fit to Gompetz
growth curves according to
[1]
where y is defined as the fluorescence signal at time t, ti corresponds to the inflection point
of the curve or the time of maximum growth rate, A is the maximum fluorescence observed
for a given sample, and b =1/kapp, where kapp is the rate constant of aggregation, in units of
s−1. The pre-growth curve exponential, e(−k′t), was inserted into the traditional Gompetz
growth curve equation to take into account the slow decrease in fluorescent intensity
resulting from ThS bleaching, quenching and gravitational precipitation of the amyloid-ThS
complex (40,48). Each experiment showing peptide aggregation was run 3 times and the
error in fitted parameters was determined from the standard deviation of the fitted
parameters. Kinetic data for mixtures of some peptides were fit to a sum of growth curve
functions according to
[2]
where b′ = 1/k′app.
2N4R tau experiments
Site directed tau mutants M11K, F378K and Y394K were generated from 2N4R tau (pT7C-
htau40 (a gift from Dr. Jeff Kuret)) using the Stratagene QuikChange Site-Directed
Mutagenesis kit following manufacturer’s protocols. Primers for site-directed mutagenesis
were synthesized by Integrated DNA Technologies. The 6x his-tagged proteins were
purified using Ni2+ charged Chelating Sepharose Fast Flow chromatography, followed by
Superdex 200 gel filtration chromatography as previously described (49). 2 μM of wild type
or mutants of 2N4R tau (M11K, F378K, and Y394K) were incubated with 75 μM
arachidonic acid in polymerization buffer (100 mM NaCl, 10 mM Hepes pH 7.64, 0.1 mM
EDTA, 5 mM DTT) for 240 minutes at room temperature. Right angle laser light scattering
(LLS) readings were taken at various time points, and images were analyzed by Adobe
Photoshop for histogram intensity of the light scattering band (50). Data was fit to the
Gompertz growth curve as previously described. A (final extent of polymerization), kapp
(proportional to the rate of polymerization), and lag (time until significant polymerization),
which equals ti-b, were determined as the mean ± SEM of 3 trials (51). After 240 minutes,
reactions were diluted 1:10 and fixed with 10% glutaraldehyde. TEM grids were prepared
and filaments were stained with 2% uranyl acetate. Images were collected at 3600x using a
Technai F20 XT Field Emission TEM (FEI). Quantitation of 5 TEM images for filament
number, length and mass per field was done using Image Pro Plus 6 with a minimum length
cutoff of 15 nm.
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Amyloidogenic sequences in tau protein
In a previous study we used a family of tau related peptides, AcVQIVXK, to define an
amyloidogenic propensity of the amino acid residue X based on a group of experimental
observables typically used to define amyloid (40). We found that peptide sequences with an
amphiphilic motif (X)nZ, where X is a hydrophobic residue and Z is a charged or polar
amino acid, have a high propensity to act as nucleating sequences. Others have shown that
amphiphilic sequences in which hydrophobic and polar residues alternate above and below
the extended peptide chain ((XZ)n (n≥2)) or have a Z(X)nZ motif also have a high tendency
to nucleate amyloid formation (24,52–55). We scanned tau protein for these amyloid-
forming motifs and calculated their amyloidogenic propensities using their constituent
residue amyloidogenic propensity scores. Using this approach we found 20 high propensity
sequences (Fig. 1): 8 sequences
(5RQEFEV, 10VME, 17TYGLG, 28GYTMHQDQ, 40DAGLK, 87KQAAAQ, 126RMV, 225K
VAVVR) in the N-terminal region, 6 in the microtubule binding region (242RLQ in
R1; 275VQIINK (PHF6*) and 282LDLSN in R2; 306VQIVYK (PHF6) in R3; 337VEVK
and 343KLDFK in R4), and 6 in the C-terminal region
(375KLTFR, 382AKAK, 393VYK, 419MVD, 428LAD, 432VSASL). Of these, PHF6* and
PHF6 in the MTBR have been shown experimentally to act as nucleating sequences in tau
related peptides or full length tau protein (19).
TEM of predicted amyloid forming sequences in tau
We prepared all 20 predicted amyloidogenic sequences as their N-acetyl peptide amides,
since N- and C-terminal charges have been shown to have a profound effect on the ability of
a peptide to form amyloid (56). We studied the behavior of these peptides in the presence of
HMW heparin, a known polyanion inducer of tau protein aggregation (19,29,45,46,57–60).
Using TEM, we observed fibers with diameters between 3 – 7 nm for Ac5RQEFEV,
Ac40DAGLK, AcPHF6*, AcPHF6, Ac343KLDFK, Ac375KLTFR, Ac393VYK, and
Ac419MVD following overnight incubation in MOPS-Cl buffer with HMW heparin (MOPS-
Cl-HMWH; Fig. 2). We also observed tubes, ribbons and rolled sheets for Ac10VME,
AcPHF6*, and Ac375KLTFR. TEM data for these peptides can be found in Table 1.
TEM is perhaps the most sensitive measure of the ability of a peptide to form amyloid since
the hydrophobic nature of amyloid structures are attracted to the hydrophobic surface of the
carbon-coated TEM grid. Previously, we observed amyloid fibers formed from peptides
containing proline, a known β-sheet breaking amino acid residue. However, it was later
determined by other measurements that the majority of the peptide existed in a random coil
conformation (40). Hence, the TEM experiment is biased toward the observation of
amyloid-like structures, even when only a relatively small fraction of the sample forms
amyloid. Equally important are those sequences that were not observed to form amyloid
structures by TEM. These sequences can be eliminated as nucleating sequences and are less
likely to affect the kinetics of amyloid formation by their interaction with other nucleating
sequences in the protein.
CD of predicted amyloid forming sequences in tau
We used CD spectroscopy to study the conformation of the predicted amyloid forming
sequences in tau. In water, the CD of AcPHF6 (Fig. 3A) and AcPHF6* (not shown)
displayed a pattern characteristic of random coil peptides with near zero ellipticity at higher
wavelength and a single negative band present near 195 nm. Under these conditions these
nucleating peptides possess a very low fraction of characteristic of aggregating species
having a significant fraction of β-sheet structure. In MOPS-Cl-HMWH, the CD spectra of
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AcPHF6* and AcPHF6 showed classical spectra of extended β-sheet, with a negative nπ*
band at 217 nm and a positive ππ* band near 198 nm (23,61). With the exception of
Ac393VYK and Ac10VME, other peptides studied showed patterns characteristic of random
coil peptides in MOPS-Cl-HMWH. The tripeptides Ac393VYK and Ac10VME displayed a
CD spectra which appeared to be a combination of spectra arising from β-sheet and random
coil structures, having a negative shoulder between 215 and 220 nm and a strong negative
band below 198 nm.
We used CD to study the interaction between peptides in MOPS-Cl-HMWH. Figure 3B
shows the CD of AcPHF6, Ac10VME, a 1:1 mixture of the two peptides and the CD that
would be calculated from the spectra of the peptides by themselves, in the absence of any
interaction. As expected, there is a negative 215 nm band for the calculated spectra for
AcPHF6 and Ac10VME (dashed line), with an intensity that is half way between that for the
spectra of the two peptides alone. In contrast, the observed CD spectrum for a 1:1 mixture of
the two peptides (solid line) has a negative 215 nm band with an intensity significantly more
negative than the calculated spectrum, suggesting that Ac10VME interacts with AcPHF6 to
shift the equilibrium towards the aggregated form. It is also noteworthy that the observed
spectrum of the 1:1 mixture shares an isodichroic point at 205 nm with the spectra of the two
isolated peptides, suggesting that only two forms of the peptides, monomeric and
aggregated, are present (37). A plausible model for this type of interaction is one in which
Ac10VME participates in the same β-sheet structure characteristic of the AcPHF6
amyloidogenic state. In contrast, the spectrum of a AcPHF6:AcPHF6* mixture (Fig. 3C)
does not appear to share an isodichroic point with spectra of the two pure peptides,
suggesting a type of interaction involving something more complex than a simple two state
model.
We define a positive interaction as one in which the observed CD of a 1:1 mixture is more
negative above (higher wavelength) the isodichroic point and more positive below this point.
In contrast, a negative interaction implies that a smaller fraction of the sample exists in an
aggregated state when the two peptides are mixed. A summary of the results is presented in
Fig. 3D. The greatest positive interactions with AcPHF6 result from peptides Ac10VME,
AcPHF6*, Ac375KLTFR and Ac393VYK while the greatest positive interactions with
AcPHF6* result from AcPHF6, and from C-terminal sequences Ac375KLTFR, Ac393VYK,
Ac419MVD, Ac428LAD, and Ac432VSASL. It should be noted that interactions evaluated in
this manner are a reflection of pairwise interactions at thermodynamic equilibrium and do
not necessarily reflect how these interactions will affect aggregation kinetics.
Kinetics of tau peptide aggregation
The kinetics of aggregation of tau peptides was measured in MOPS-Cl-HMWH by
following the time dependence of ThS fluorescence at 490 nm, and fitting the data to
Gompertz growth curves (20,40,41,45,47,48). Under these conditions only AcPHF6 and
AcPHF6* displayed measurable aggregation (kapp = 23.3±1.4 × 10−3 s−1 and 9.2±0.7 × 10−3
s−1, respectively). We also measured aggregation of these two peptides in the presence of
the other predicted amyloidogenic peptides by mixing peptides at a 1:1 stoichiometric ratio.
Only Ac275KLTFR had any significant effect on the aggregation (p≤0.05), slowing the
aggregation kinetics of both AcPHF6 and AcPHF6* (19.4 ± 0.5 × 10−3 s−1 and 3.9 ± 0.6 ×
10−3 s−1). The effect of Ac275KLTFR on the aggregation of AcPHF6* is shown in Fig. 4A
as a function of increasing Ac275KLTFR:AcPHF6* stoichiometry. At less than a 1:1
stoichiometric ratio Ac275KLTFR acts as an aggregation inhibitor, affecting both the kapp
and the lag time, while at a 2:1 Ac275KLTFR:AcPHF6* stoichiometric ratio there are two
discernable aggregation events. Plots of log(kapp) and lag time obtained from fitting vs.
Ac275KLTFR:AcPHF6* stoichiometry for the first aggregation event showed a linear
Moore et al. Page 6













relationship (Fig. 5; r2 ≥ 0.97), suggesting that both nucleation and elongation are affected
in a nucleation-elongation mechanism.
We found it surprising that Ac275KLTFR was an inhibitor of AcPHF6 and AcPHF6*
aggregation, but that Ac343KLDFK, a peptide whose sequence is homologous, was not. We
hypothesized that it may be the charge-charge repulsion between aspartic acid sidechains
that led to its inability to fit into the AcPHF6 or AcPHF6* steric-zipper structure. To test
this hypothesis we measured the aggregation of AcPHF6* at different stoichiometric ratios
of Ac343KLDFK:AcPHF6* in phosphate buffer at pH 3.0, where the aspartic acid carboxyl
is uncharged (Fig. 4B). Under these conditions Ac343KLDFK inhibits the aggregation of
AcPHF6* in a dose-dependent manner, similar to the inhibition by Ac275KLTFR at higher
pH. A plot of log(kapp) vs. Ac343KLDFK:AcPHF6* stoichiometry was linear (Fig. 5A) but
we did not observe a linear dependence in lag time with increasing Ac343KLDFK
concentration.
Fig. 4C shows the effect that mixing AcPHF6* with AcPHF6 at 1:1 stoichiometry has on
aggregation kinetics. Using the same fitted kinetic parameters that we obtained from the
kinetics of AcPHF6 and AcPHF6* aggregation, we simulated the aggregation of the
AcPHF6:AcPHF6* mixture from a sum of growth curves (dashed line). While the curve
comes close to the observed data at short times, it deviates from the data at longer time
points. The data could be fit to a sum of growth curves by varying the kinetic parameters for
both AcPHF6 and AcPHF6* (solid line) and we found the best fit could be obtained with a
significantly faster kapp for AcPHF6* (46 ±3 × 10−3 s−1) and a significantly slower kapp for
AcPHF6* (5.6 ± 0.6 × 10−3 s−1), again suggesting a complex kinetic interaction between
these two peptides.
Aggregation kinetics of 2N4R tau mutants
While the CD interaction experiments and kinetic studies on predicted amyloidogenic tau
peptides suggest that interactions between sequences may effect tau aggregation rate or the
overall fraction of tau participating in an aggregated state, they do not address whether such
interactions take place intra- or intermolecularly or what additional constraints the full
protein may impose. To address this issue we prepared 3 single site mutants of tau (M11K,
F378K, and Y394K) that were predicted to decrease the amyloidogenic propensities
of 10VME, 275KLTFR and 393VYK by substituting a positively charged lysine for a
hydrophobic residue (40). Kinetics of polymerization for 2N4R lysine mutants were assayed
by right angle laser light scattering against wild-type tau (Figure 6A). M11K showed a
significantly longer lag time than WT (12.69 ± 3.41 min compared to 7.20 ± 0.61 min; p ≤
0.05) while F378K and Y394K showed no significant difference (7.41 ± 0.07 min and 7.22
± 0.42 min respectively). The kapp for M11K decreased significantly (0.09 ± 0.03; p ≤ 0.05),
while the kapp for F378K (0.17 ± 0.05) and Y394K (0.15 ± 0.007) were slightly larger than
kapp for WT (0.13 ± 0.02). M11K, F378K and Y394K showed a trend for slightly higher
maximum light scattering values (126.63 ± 18.92, 110.50 ± 13.55, and 113.87 ± 15.16
respectively) than WT (95.40 ± 5.22). TEM images, however, showed no difference in the
morphology of filaments (Figure 6B-E). Quantitation of filaments revealed M11K had
significantly fewer filaments, while F378K had significantly more filaments (p ≤ 0.0001)
and Y394K had approximately the same number as compared to WT (Figure 6F). Filament
lengths were only increased in M11K as compared to WT, with F378K and Y394K having
the same average length of filaments per field (Figure 6G). The mass of filaments per field
(length × number) was similar to the changes seen for the number of filaments per field
(Figure 6H).
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Whether or not proteins form amyloid depends on the presence of nucleating sequences or
“hot spots”, short sequences of amino acids that have a high propensity (HP) to form parallel
or anti-parallel β-sheet structure between protein monomers (62–65). However, the presence
of these nucleating sequences is not a sufficient condition for oligomerization, particularly
for most proteins where HP sequences occur on the interior of the protein (63,66).
Perturbation of the protein away from its native conformation, either by partial denaturation
or by the presence of mutations, controls the exposure of these sequences to the solvent and
thus controls their ability to interact intermolecularly with other monomers and form toxic
oligomers or filaments (62,64). In “natively unfolded” proteins or peptides, HP sequences
may inhibit the formation of amyloid, either by controlling the folding of the backbone or by
forming intramolecular β-structure (62,67,68). Tau is a loosely folded flexible protein with
two nucleating sequences, PHF6* and PHF6 at the beginning of R2 and R3 in the MTBR
(19,31,69). The PHF core is formed by only a portion of tau near the C-terminal, including
the MTBR, while N-terminal forms the outer “fuzzy coat” of PHF (14,70–72). Shorter tau
related peptides containing PHF6 & PHF6* aggregate much more rapidly than full length
tau, suggesting that other segments of the full length protein assume a regulatory role by
interacting intramolecularly with the MTBR region (23,40,73). Other segments of tau distant
from the nucleating PHF6 and PHF6* regions, such as the N-terminal inserts, tend to
promote aggregation (33,38).
Given the evidence suggesting that regions of tau remote from the MTBR are instrumental
in regulating polymerization, we were curious to see if (1) HP sequences, other than PHF6
and PHF6*, could nucleate filament formation and (2) HP sequences could interact with the
known nucleating sequences PHF6 or PHF6* to increase the fraction of β-sheet structure
present or to control aggregation kinetics. We scanned tau for HP motifs and quantitated
their propensities using an algorithm previously described by us (40). Other algorithms exist
for determining sequence amyloidogenic propensity based on sequence or on their
interaction energy with other nucleating sequences (58,74–77). While they are able to find
PHF6 and PHF6* in tau, no other potential HP regions have been reported. Our model
flagged 20 HP sequences, including 87KQAAAQ, 225KVAVVR, and 337VEVK, in addition
to PHF6 and PHF6*. These sequences have previously been shown to populate β-sheet
structure by NMR studies of full length tau protein (31). In summary, our simple method of
finding potential HP regions of tau is capable of locating sequences that other more complex
algorithms can not, although it may be that our method is so sensitive that it flags sequences
which neither form amyloid nor interact with other known nucleating sequences.
We used TEM to experimentally evaluate the amyloid forming propensity of N-acetylated
peptide amides with sequences identical to the 20 HP sequences in tau flagged by our
algorithm. Filaments and tubes were observed for N-terminal peptides Ac5RQEFEV10 and
Ac10VME. In the past, a Δ2–18 mutant has been shown to aggregate less effectively than
wild type tau, suggesting that residues in the N-terminal help seed aggregation in the
presence of arachidonic acid inducer (33). Tau with frontotemporal dementia mutation R5L
aggregates faster than wild type tau and forms 4.5 times more filaments, again emphasizing
the role this segment plays in oligomerization (33). We observed rolled sheets, fibers and
ribbons for AcPHF6* and filaments for AcPHF6 and Ac343KLDFK. These sequences occur
in the MTBR and have previously been shown by NMR to populate β-sheet structure
(31,57,78,79). We observed no amyloid structures for Ac87KQAAAQ, Ac225KVAVVR, or
Ac337VEVK, sequences which were observed to populate β-structure in the NMR of full
length tau (31). We observed rolled sheets and fiber bundles for Ac375KLTFR, a sequence in
tau which lies just downstream of R4, and has been shown by NMR to be in an inflexible
region of PHFs (69). We have previously shown that Ac393VYK forms filaments, and
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mixtures of AcPHF6 and Ac393VYK form twisted filaments with identical morphology to
bona fide PHFs (23). The 392IVYK sequence likely is the nucleation sequence for the
amyloid formed from the 383-337 C-tail 8 peptide, previously shown to possess a high
degree of β-sheet structure and form filaments in the absence of polyanion inducer (37). We
also observed fibers and spherical aggregates for the peptide Ac419MVD. Caspase-3
mediated cleavage after Asp421 can be detected in mild cognitive impairment and AD but
not in non-demented control brains (7). It is tempting to speculate that C-terminal truncation
at this site may allow the 419MVD sequence sufficient solvent accessibility to help seed
oligomerization.
Only AcPHF6 and AcPHF6* showed measurable aggregation kinetics as well as a high
fraction of β-structure at equilibrium determined by CD. Of the peptides shown by TEM to
form amyloid, Ac10VME, AcPHF6*, Ac375KLTFR, and Ac393VYK were found to enhance
the fraction of β-structure of AcPHF6 formed at equilibrium, and Ac375KLTFR was found
to affect AcPHF6 and AcPHF6* aggregation kinetics. Others have shown that interactions
between PHF6 and PHF6* exist in tau or tau related peptides (19–22,27,28). Ac375KLTFR
slowed the aggregation kinetics of AcPHF6 by roughly 15% but slowed the kapp for
AcPHF6* aggregation by 60% at 1:1 stoichiometry. We obtained linear plots of log(kapp) or
lag time for the first aggregation event versus the Ac375KLTFR/AcPHF6* ratio, suggesting
that Ac375KLTFR acts as a competitive inhibitor of AcPHF6* aggregation. Given the
sequence homology between Ac375KLTFR and Ac343KLDFK, we found it surprising that
Ac343KLDFK was not also an inhibitor of AcPHF6* aggregation. However, we found that
Ac343KLDFK was an inhibitor at pH 3.0 where the carboxyl of the aspartic acid sidechain is
protonated. Apparently its limited ability to inhibit AcPHF6* aggregation arises from
unfavorable interaction between the charged carboxylate sidechains in the peptide at neutral
pH. Both Ac343KLDFK and Ac375KLTFR satisfy a model based on the steric-zipper where
they occur in alternating layers with AcPHF6*. A hypothetic model shows antiparallel
layers of parallel in-register peptide β-structure (Fig. 7) (24,25).
Although data from studies with HP peptides suggest that the sequences 10VME, 375KLTFR
and 393VYK have the potential of interacting with PHF6 and PHF6* to enhance the fraction
of amyloid present or inhibit the rate of aggregation, it is difficult to predict how these
interactions will influence tau aggregation without having some idea of solvent accessibility.
Intramolecular interactions which enhance amyloid formation might be expected to inhibit
oligomerization while similar intermolecular interactions would be expected to enhance it.
In the past, we and others have shown that two consecutive C-terminal positively charged
residues transform an amyloidogenic sequence into a non-amyloidogenic one (40,41,55). In
the case of the M11K mutant, fewer filaments were observed and there was an increase in
lag time and a decrease in the rate of aggregation compared to wild type tau, suggesting that
the N-terminal sequence 10VME enhances arachidonic acid induced nucleation and
elongation. In contrast, the F378K mutant showed an increased rate of aggregation and more
filaments compared to wild type tau. Because of the proximity of the 375KLTFR sequence to
PHF6 and PHF6*, it is tempting to speculate that the region just downstream of MTBR
interacts intramolecularly with these nucleating sequences, protecting them from interacting
intermolecularly. The Y394K mutant produced about the same number of filaments and had
a similar rate of aggregation as wild type tau. This result is consistent with NMR evidence
which shows that 392IVYK does not form β-structure in full length tau (31,37,59).
In conclusion, we have shown that HP sequences in tau other than PHF6 and PHF6* can
nucleate amyloid formation and can help regulate the kinetics of amyloid formation. That
being said, amyloid nucleation is a complex event in tau, governed by the folding of the
peptide backbone, phosphorylation of amino acid side chains, environmental conditions
(reducing or non-reducing, salt concentration, pH), the nature of polyanionic or long chain
Moore et al. Page 9













fatty acid inducers, and other HP sequences remote from the primary nucleating site
(16,31,36,60). These secondary HP sequences in tau or other proteins may have evolved in
order to protect biological systems from protein oligomerization and toxicity.
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MTBR microtubule binding region
R1–R4 32 amino acid pseudorepeats 1 – 4 in the MTBR
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MALDI-TOF MS matrix assisted laser desorption/ionization mass spectrometry
ESI electrospray ionization
FRET fluorescent resonant energy transfer
PC1 scores principal component scores
LLS right angle laser light scattering
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(A) Schematic of full-length tau showing the 20 sequences which fit the motifs (X)nZ or
Z(X)nZ (n≥2) or (XZ)n (n≥2), where X is a hydrophobic residue and Z is a charged or polar
amino acid. The model assumes that these sequences have a high propensity to act as
nucleating sequences in amyloid formation. (B) Amyloidogenic propensities for sequences
calculated by taking the sum of the absolute values of constituent amino acid propensities
(40).
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TEMs of high propensity peptide sequences in MOPS-Cl-HMWH buffer. Scale bar
represents 100 nm.
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(A) Far-UV CD spectra of 100 μM N-acetylated peptide amides in water or MOP-Cl-
HMWH buffer (pH 7.2). (B) CD of AcPHF6, Ac10VME (MOPS-Cl-HMWH), the calculated
mean residue ellipticity of a 1:1 stoichiometric mixture, and the observed ellipticity of the
mixture. (C) as in (B) for AcPHF6 and AcPHF6*. (D) Difference between calculated and
observed ellipticity for the peptides. A positive interaction is one in which the observed CD
of a 1:1 mixture is more negative above (higher wavelength) the isodichroic point and more
positive below this point. In contrast, a negative interaction infers that a smaller fraction of
the sample exists in an aggregated state when the two peptides are mixed.
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Aggregation kinetics of peptides and peptide mixtures in MOPS-Cl-HMWH followed by
fluorescence of ThS at 490 nm (440 nm excitation). AcPHF6* was 100 μM. (A) AcPHF6*
(filled circles), AcPHF6*:Ac375KLTFR at 2:1 (filled squares), 1:1 (filled triangles) and 1:2
stioichiometry (crosses), in MOPS-Cl, pH 7.2. Solid lines represent best fits to the data,
assuming a single Gompetz growth curve model for pure AcPHF6* and
AcPHF6*:Ac375KLTFR mixtures at less than 1:1 stoichiometry. The
AcPHF6*:Ac375KLTFR mixture at 1:2 stoichiometry was modeled using a sum of Gompetz
growth curves (Eq. [2]). (B) as in (A) with AcPHF6* and AcPHF6*:Ac343KLDFK mixtures
in phosphate-Cl buffer at pH 3.0. (C) Aggregation kinetics of AcPHF6 (filled circles),
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AcPHF6* (filled triangles), and a 1:1 stoichiometric mixture of AcPHF6:AcPHF6*. Solid
lines represent best fits to a single Gompetz growth curve, in the case of pure peptides, or a
sum of two Gompetz growth curves, in the case of the mixture. The dashed line represents a
sum of fitted curves for AcPHF6 and AcPHF6*, assuming no interaction between the
peptides.
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Plots of parameters obtained from fitting kinetic data for AcPHF6* and
AcPHF6*:Ac375KLTFR and AcPHF6*:Ac343KLDFK mixtures. (A) Log(kapp) for first
aggregation event of AcPHF6* and AcPHF6*:Ac375KLTFR mixtures at pH 7.2 (filled
diamonds) and for AcPHF6* and AcPHF6*:Ac343KLDFK mixtures (exempting
AcPHF6*:Ac343KLDFK at 1:2 stoichiometry) at pH 3.0 (open diamonds). (B) Lag time for
first aggregation event of AcPHF6* and AcPHF6*:Ac375KLTFR mixtures. Data could be fit
with an r2 > 0.97.
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2N4R lysine mutants show variations from WT tau. Mutant forms (M11K, F378K, and
Y394K (diamond, triangle and square respectively)) and WT (circle) 2N4R tau were assayed
by LLS over the course of 240 minutes (first 100 minutes shown) (A). Data was fit to the
Gompertz growth curve (M11K, F378K, Y394K and WT (solid, long/short dash, short dash
and long dashed lines respectively)). Representative TEM images of WT (B), M11K (C),
F378K (D), and Y394K (E) were collected at 3600x magnification. Images were quantitated
using Image Pro Plus for filament number (F), length (G), and mass (H). Data in F-H are
averages of 5 fields ± SEM (p ≤ 0.0001 for bars marked with asterisks). Scale bar represents
1 μm.
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Hypothetical model for AcPHF6 and Ac375KLTFR in hybrid steric zipper. At 1:1
stoichiometry antiparallel layers of parallel in-register chains of AcPHF6 and Ac375KLTFR
continue to form amyloid, albeit at a reduced rate of aggregation.
Moore et al. Page 22

























Moore et al. Page 23
Table 1
TEM results for tau-related peptidesa
Peptide Amyloid Structures Fiber/Tube Diameter(nm)
Ac5RQEFEV fiber bundles 2.7 (±0.4)
Ac10VME tubes 20.3 (±1.5)
Ac17TYGLG n.o.
Ac28GYTMHQDQ n.o.




AcPHF6* rolled sheets, fibers, ribbons 5.5 (±1.3)
Ac282LDLSN n.o.
AcPHF6 fibers 6.5 (±1.2)
Ac337VEVK n.o.
Ac343KLDFK fibers 3.3 (±0.4)
Ac375KLTFR rolled sheets, fiber bundles 4.0 (±0.9)
Ac382AKAK n.o.
Ac393VYK fibers 5.3 (±0.4)




Results labeled as “n.o.” indicates no amyloid structures were observed.
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